HSCI has received approval from the Russian Ministry of Health to begin clinical trials of the coronavirus vaccine Betuvax-CoV-2. The drug consists of nanoparticles that mimic the SARS-CoV-2 coronavirus but are not capable of infecting mammals. Phase I and Phase II trials will run from September 27, 2021 to August 31, 2022.